Stephen Gardner to Hepatitis C, Chronic
This is a "connection" page, showing publications Stephen Gardner has written about Hepatitis C, Chronic.
Connection Strength
0.976
-
A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects. Liver Int. 2014 Jul; 34(6):e89-95.
Score: 0.413
-
Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C. Liver Int. 2015 Feb; 35(2):429-37.
Score: 0.111
-
Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2014 Dec; 12(12):2113-20.e1-3.
Score: 0.107
-
Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection. Hum Genet. 2012 Dec; 131(12):1911-20.
Score: 0.095
-
Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol. 2011 Dec; 55(6):1195-200.
Score: 0.087
-
Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology. 2010 Jun; 51(6):1904-11.
Score: 0.082
-
Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology. 2010 Apr; 138(4):1365-73, 1373.e1-2.
Score: 0.080